Trials / Completed
CompletedNCT00041704
The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)
A Phase 2 Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Anidulafungin is an antifungal agent of the echinocandin class which is highly active in vitro against fluconazole resistant Candida species. The efficacy of anidulafungin has demonstrated in various animal models of fluconazole-resistant mucosal disease; as well as, in Phase 2 Esophageal Candidiasis studies. This study is intended to offer patients with FRMC an alternate therapy with amphotericin B or with other agents whose efficacy and/or safety are inadequate in the treatment of this disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anidulafungin, VER002 |
Timeline
- Start date
- 2002-08-01
- Completion
- 2004-08-01
- First posted
- 2002-07-16
- Last updated
- 2008-10-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00041704. Inclusion in this directory is not an endorsement.